10-Q: Veru Reports Q1 Loss, Boosts Cash with Offering, Advances Pipeline

Veru Inc. reported an increased net loss from continuing operations for Q1 2026 but significantly improved its cash position through a public offering, while advancing its enobosarm and sabizabulin drug candidates.

Summary

• Net loss from continuing operations for the three months ended December 31, 2025, was $5.33 million, compared to $1.81 million for the same period in 2024.
• Overall net loss decreased to $5.33 million from $8.95 million in the prior year, primarily due to the absence of discontinued operations and a gain on debt extinguishment in the comparative period.
• Cash, cash equivalents, and restricted cash increased to $32.99 million as of December 31, 2025, from $15.79 million at September 30, 2025.
• The company completed an underwritten public offering on October 31, 2025, raising approximately $23.4 million in net proceeds.
• Research and development expenses decreased to $1.34 million from $5.72 million in the prior year, attributed to the wind-down of the Phase 2b QUALITY clinical study for enobosarm.
• General and administrative expenses decreased to $4.08 million from $5.23 million in the prior year, mainly due to reduced share-based compensation.
• Veru sold its FC2 Female Condom business on December 30, 2024, for $18.0 million, resulting in a $4.1 million loss on sale.
• The company settled its ENTADFI asset sale promissory notes with Onconetix, Inc. (ONCO) on September 22, 2025, receiving $6.3 million in cash, 3,125 shares of ONCO Series D Preferred Stock, and a warrant to purchase 846,975 shares of ONCO common stock.
• A 1-for-10 reverse stock split was effected on August 8, 2025.
• Substantial doubt exists regarding the company's ability to continue as a going concern for the next twelve months, despite the recent capital raise.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with cautious optimism. While the positive clinical data for enobosarm and the successful capital raise are significant positives, the explicit 'going concern' warning and ongoing legal challenges present substantial risks and overshadow some of the clinical progress.

Positives

• Cash, cash equivalents, and restricted cash significantly increased to $32.99 million, providing improved liquidity.
• Positive topline results from the Phase 2b QUALITY clinical trial for enobosarm demonstrated statistically significant preservation of lean body mass (100% relative reduction in lean mass loss, p<0.001) and dose-dependent greater fat loss.
• Enobosarm treatment reduced the proportion of patients with a clinically significant stair climb physical function decline by 59.8% (p=0.0006) in the 3mg dose group.
• The enobosarm + semaglutide combination showed a positive safety profile with no increases in gastrointestinal side effects, liver injury, obstructive sleep apnea, PSA in men, masculinization in women, or suicidal ideation.
• Enobosarm 3mg + semaglutide combination had the added benefit of fewer gastrointestinal side effects compared to semaglutide alone.
• The 12-week maintenance extension study showed enobosarm 3mg monotherapy significantly reduced body weight regained by 46% after discontinuing semaglutide, while preserving lean mass and promoting greater fat loss.
• FDA feedback provides clear regulatory pathways for enobosarm, accepting incremental weight loss as a primary endpoint and confirming enobosarm 3mg as an acceptable dosage.
• The FDA's recent announcement that total hip bone mineral density (BMD) qualifies as a validated surrogate endpoint for osteoporosis could benefit enobosarm's development, given its preclinical data showing increased BMD.
• The sabizabulin program for atherosclerotic cardiovascular disease is advancing, with FDA agreement on unmet medical need and a planned Phase 2 dose-finding study.
• Sabizabulin has a different chemical structure than colchicine, potentially eliminating drug-drug interactions associated with colchicine, a significant safety advantage.

Negatives

• Net loss from continuing operations increased to $5.33 million for the three months ended December 31, 2025, from $1.81 million in the prior year period.
• The company explicitly states that substantial doubt exists regarding its ability to continue as a going concern for the next twelve months.
• The company is not profitable and has had negative cash flow from operations, requiring substantial capital for drug development.
• Ongoing shareholder litigation (Ewing, Maglia, Franchi, Renbarger, Alshourbagy, Ovadias lawsuits) alleges false statements about sabizabulin for COVID-19, breach of fiduciary duty, and other claims, with potential unestimable losses.
• A lawsuit from Clear Future, Inc. (purchaser of FC2 business) alleges breach of representations and warranties, fraud, and indemnification for a pre-closing tax liability, with unestimable potential losses.

Risks

• Potential delays in the timing of and results from clinical trials and studies, including patient recruitment and participation, and the risk that results will not support marketing approval.
• Potential delays in, or failure to obtain, FDA or other regulatory authority approval for products under development, including disagreement on clinical trial design.
• The FDA may ultimately disagree that clinical trials support approval, despite prior feedback.
• Risks related to the ability to obtain sufficient financing on acceptable terms to fund product development and operations, and to continue as a going concern.
• Inability to maintain compliance with Nasdaq continued listing requirements.
• Need to secure significant external funding (grants, partnerships) to advance sabizabulin development for atherosclerosis.
• Product demand and market acceptance of products in development, if approved, may be lower than anticipated.
• Inability to obtain insurance reimbursement from private or government payors for approved products.
• Risks related to intellectual property, including obtaining and enforcing protections, potential infringement, and funding for defense.
• Competition from existing and new competitors, potentially leading to reduced sales, pricing pressure, and increased marketing costs.
• Risks related to compliance and regulatory matters, including costs and delays from extensive government regulation and healthcare reform measures.
• Risks inherent in international business, including currency risks, tariffs, political risks, and export restrictions.
• Risk of disruption of production at third-party facilities due to raw material/labor shortages, manufacturing partner changes, or other issues.
• Risks relating to the restatement of prior financial statements.
• Risks relating to a history of losses and no current commercial revenue, with no guarantee of future profitability.
• Cybersecurity risks and potential data security or privacy incidents affecting information technology systems.
• Inability to identify, negotiate, and complete suitable acquisitions, out-licensing, in-licensing, or other strategic initiatives.

Future Outlook

The company plans to focus its Phase 2b PLATEAU clinical study for enobosarm in older patients (age >= 65, BMI >= 35) initiating GLP-1 RA treatment, with the study expected to begin in Q1 calendar 2026 and interim analysis planned for Q1 calendar 2027. This study aims to achieve clinically meaningful incremental weight reduction and preserve muscle mass and physical function. Based on FDA feedback, results from the PLATEAU study may lead to three possible Phase 3 regulatory pathways for approval, focusing on incremental weight loss, physical function, or bone mineral density as primary endpoints. For sabizabulin, the company plans to evaluate it in a small Phase 2 dose-finding proof-of-concept study to assess its ability to reduce high sensitivity C-reactive protein levels in patients with stable coronary artery disease.

Management Comments

• Management believes there is an urgent unmet need for a drug that prevents the loss of muscle and increases the loss of fat for greater weight loss in at-risk sarcopenic obese and overweight older patients receiving GLP-1 RA for weight reduction.
• Management believes enobosarm is a novel drug candidate that improves GLP-1 RA therapy, resulting in tissue-selective quality weight reduction.
• Management believes treatment with semaglutide when combined with enobosarm, will lead to additional fat loss by preserving muscle and physical function, resetting the weight loss plateau.
• Management believes there is compelling scientific evidence and rationale to evaluate sabizabulin as a treatment for the inflammation associated with atherosclerotic cardiovascular disease.
• Management's decision to explore the cardiometabolic indication for sabizabulin was based on the significant unmet medical need, large global market opportunity, existing clinical and safety database, high probability of success of the drug's mechanism of action, and strong intellectual property position.

Industry Context

StockSavvy.ai notes that Veru Inc. is strategically positioning its lead drug candidate, enobosarm, to address a critical unmet need in the rapidly expanding obesity treatment market, specifically by mitigating muscle loss associated with GLP-1 RA therapies like Wegovy. This approach aligns with a growing industry focus on 'quality weight loss' and improved body composition. The company's sabizabulin program targets atherosclerotic cardiovascular disease, leveraging the recent FDA approval of colchicine for this indication, but aiming to offer a safer alternative by avoiding drug-drug interactions common with existing treatments. This dual focus places Veru in two high-growth, high-need therapeutic areas, but also against established players and significant development hurdles.

Comparison to Industry Standards

• Enobosarm's Phase 2b QUALITY study results showed 100% relative reduction in lean mass loss when combined with semaglutide, a significant improvement over the 20-50% lean mass loss typically observed with GLP-1 RA drugs alone, as noted in scientific literature.
• The study's finding that 44.3% of patients on placebo + semaglutide experienced at least a 10% decline in stair climb power highlights a significant issue with GLP-1 RA monotherapy in older patients, which enobosarm aims to address.
• The FDA's recent approval of colchicine for reducing cardiovascular events in adults with established atherosclerotic cardiovascular disease sets a precedent for anti-inflammatory drugs in this space, which sabizabulin aims to improve upon by potentially eliminating drug-drug interactions common with colchicine (e.g., with statins like those used in the SELECT trial by Novo Nordisk A/S).
• The observation that GLP-1 RA therapy reduces hip bone mineral density and increases fracture risk (as seen in Novo Nordisk A/S's SELECT cardiovascular trial for Wegovy) provides a new opportunity for enobosarm, given its preclinical data showing increased BMD, potentially offering a differentiated benefit compared to current GLP-1 RA treatments.

Corporate Governance

Legal Proceedings

• Ewing v. Veru Inc., et al. (Case No. 1:22-cv-23960): A putative class action alleging false statements about sabizabulin for COVID-19, seeking monetary damages.
• Maglia v. Steiner et al. (Case No. 2023-019406-CA-01): A derivative action alleging breach of fiduciary duty, waste of corporate assets, and unjust enrichment, seeking corporate governance improvements and monetary damages.
• Franchi v. Steiner et al. (Case No. 2:23-CV-01164) and Renbarger v. Steiner et al. (Case No. 2:23-CV-01291): Consolidated derivative actions alleging breach of fiduciary duty, gross mismanagement, and unjust enrichment, seeking corporate governance improvements and monetary damages.
• Alshourbagy v. Steiner et al. (Case No. 1:23-cv-23846): A derivative action alleging breach of fiduciary duty and contribution, seeking corporate governance improvements and monetary damages.
• Ovadias v. Steiner et al. (Case No. 3:24-cv-00676): A derivative action alleging breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and contribution, seeking corporate governance improvements and monetary damages.
• Clear Future, Inc. v. Veru Inc. (Case No. N25C-08-066 EMD): A lawsuit alleging breach of representations and warranties, fraud, and indemnification for a pre-closing tax liability related to the FC2 Business Sale.

Stakeholder Impact

• Shareholders: Face potential dilution from future capital raises, significant risk from the 'going concern' warning, and uncertainty from ongoing legal proceedings. However, positive clinical trial results for enobosarm and sabizabulin offer potential long-term value creation.
• Employees: Share-based compensation is a component of overall compensation. Continued operations and drug development progress are crucial for job security and morale.
• Customers/Patients: Potential beneficiaries of new treatments for obesity (enobosarm) and atherosclerotic cardiovascular disease (sabizabulin) if approved, addressing significant unmet medical needs.
• Creditors: The settlement of the commercial dispute and the extinguishment of the Residual Royalty Agreement debt reduce certain liabilities, but the 'going concern' warning indicates ongoing financial risk.

Next Steps

• Initiate the Phase 2b PLATEAU clinical study for enobosarm in older patients (age >= 65, BMI >= 35) initiating semaglutide treatment in the first quarter of calendar 2026.
• Conduct an interim analysis for the Phase 2b PLATEAU clinical study in the first quarter of calendar 2027.
• Evaluate sabizabulin in a small Phase 2 dose-finding proof-of-concept study to assess reduction in high sensitivity C-reactive protein in patients with stable coronary artery disease.
• Continue to seek additional capital through public or private equity offerings, debt financing, and/or other capital sources to fund operations and drug development.
• Address ongoing legal proceedings, including shareholder litigation and the Clear Future Lawsuit.

Key Dates

Recommendation

While Veru Inc. presents compelling positive clinical data for enobosarm and sabizabulin, and has recently bolstered its cash position through a public offering, the explicit 'substantial doubt regarding our ability to continue as a going concern' is a critical red flag for investors. This fundamental uncertainty, coupled with ongoing legal proceedings, introduces significant risk. However, the positive FDA feedback and clear regulatory pathways for enobosarm, along with the potential for sabizabulin, suggest a high-risk, high-reward scenario. A 'hold' recommendation acknowledges both the significant downside risks to viability and the potential for substantial upside if the company successfully navigates its financial challenges and achieves regulatory and commercial milestones for its promising drug candidates.

Keywords

Biopharmaceutical, Clinical Stage, Enobosarm, Sabizabulin, Obesity, GLP-1 RA, Cardiometabolic Diseases, Atherosclerotic Cardiovascular Disease, Clinical Trials, FDA Approval, Drug Development, Going Concern, Public Offering, Warrants, SEC Filing, Nasdaq